Dendritic Cell Therapy Tracking Using Magnetic Particle Imaging (MPI) Bo Yu Authors: Bo Yu, N’Quel Bonner, Ginger Moore, Angelie Rivera-Rodriguez, Sitong Liu, Fernanda Pohl-Guimarães, Duane Mitchell, Carlos Rinaldi-Ramos Faculty Mentor: Carlos Rinaldi-Ramos, PhD College: College of Engineering Department: Chemical Engineering |
|
AbstractImmunotherapy is a type of cancer treatment that activates the body’s immune system to attack cancer cells. It has emerged as a safe and effective approach to treat some cancers because of reduced side effects, longer post-treatment protection, and potential to treat metastatic disease. The use of antigen presenting cells, such as dendritic cells (DCs), for cancer immunotherapy has been of interest for several years. However, DCs must migrate to lymphoid organs to be effective, and the magnitude of anti-tumor response is correlated to DC migration to lymph nodes. Therefore, non-invasive methods to monitor and quantify migration of adoptive DC therapies to target lymph nodes would be tremendously helpful in evaluating immune response. Although techniques such as magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET) have previously been used to track DCs, these are limited by low cell sensitivity. Magnetic particle imaging (MPI) is a novel molecular imaging technology that can sensitively and quantitatively detect iron oxide magnetic tracers in vivo. Sensitivity and resolution are determined by the tracer type employed for DC labeling. Our group has recently reported a superparamagnetic iron oxide nanoparticle (SPION) tracer (RL-1) tailored for improved MPI sensitivity and suitable for cell tracking applications. In this study, RL-1 tailored tracers will be used for dendritic cell labeling and tracking to determine their biodistribution during cancer immunotherapy.
|